#### A HUMAN RESPONSE




THERE, TOGETHER WHEN IT COUNTS



Annual Shareholders' Meeting 2021

## **Online Help**



### **Your Board**



Scott St John



Lewis Gradon



Sir Michael Daniell



Pip Greenwood



Geraldine McBride



Neville Mitchell



Donal O'Dwyer



## Agenda

- Chair's Address and Board Subcommittee Updates
- Managing Director and Chief Executive Officer's Review
- Financial Statements
- Resolutions
- Voting
- General Questions



## **FY2021 Financial Highlights**

Operating Revenue

Net Profit After Tax

Dividend


\$1.97<sub>B</sub> 1.97<sub>B</sub>

\$524.2M 1 82%

**38.00**cps 1 **38**%



## **FY2021 Revenue by Product Group**





## Hospital

23.0

Fisher&Paykel

20

10

-0- -0

20

F&P MR850<sup>™</sup> Optiflow+





## **Homecare**


ישונה בבשנה ע

LAST MORD STANDS

F&P MyAirvo2<sup>™</sup> Optiflow+


## FY21 Result

Revenue	\$466M
FY21 Revenue	Growth
NZ\$	1 2%
Constant Currency	1 4%






## **Gross and Operating Margins**



Long Term Gross Margin Target – 65%

#### **Operating (EBIT) Margin**



Long Term Operating Margin Target – 30%





Research and development - \$136.7 million investment





6,000+ people





Profit-sharing bonus - \$29 million





### **Fisher & Paykel Healthcare Foundation**

# NZ \$20MILLION



## **FY22 Trading Update**

#### First four months of FY22

- Revenue \$583M, 2% below the prior comparable period in constant currency
- Hospital product group
  - Revenue down 3% cc from prior comparable period
  - 13% decline in hardware sales from prior comparable period
  - Hardware revenue remained elevated
  - Consumables revenue +2% CC\*
  - New applications consumables +17% CC\*
- Homecare product group
  - Revenue +4% CC\* from prior comparable period
  - 4% growth in OSA masks



## **Outlook for the remainder of FY22**

For the remainder of the 2022 financial year\*:

- No quantitative guidance provided given continuing uncertainties related to COVID-19
- Hospital hardware revenue not expected to continue at elevated levels
- Hospital consumables sales will continue to be impacted by COVID-19 hospitalisation rates
- New OSA patient diagnosis rates expected to be at or above FY21 rates
- Freight costs remain elevated
- Continue to grow investment in R&D and SG&A

\* Based on observations and expectations as at 18 August 2021



## **Financial Statements**

- Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor's report or the company's 2021 annual report.
- There will be an opportunity to ask any general questions once all items on the agenda have been considered.






## **Resolutions**

- 1. Re-election of Scott St John as Director
- 2. Re-election of Sir Michael Daniell as Director
- 3. Auditor's Remuneration
- 4. Issue of Performance Share Rights
- 5. Issue of Options




## How to Vote Online



## **Resolution 1: Re-election of Scott St John**

That Scott St John, who retires by rotation and, being eligible, offers himself for reelection, be re-elected as a director of the Company.



Click "Submit Vote" to lodge your vote. Need help?

Call the Link Market Services helpline 0800 200 220



## **Resolution 2: Re-election of Sir Michael Daniell**

That Sir Michael Daniell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company.



Click "Submit Vote" to lodge your vote.



## **Resolution 3: Auditor's Remuneration**

That the Directors be authorised to fix the

fees and expenses of PwC as the

Company's auditor.

Click "Submit Vote" to lodge your vote.



## **Resolution 4: Issue of Performance Share Rights**

That approval be given for the issue of up to 60,000 performance share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan to Lewis Gradon, Managing Director and Chief Executive Officer of the Company.

Click "Submit Vote" to lodge your vote.



## **Resolution 5: Issue of Options**

That approval be given for the issue of up

to 190,000 options under the

Fisher & Paykel Healthcare 2019 Share

Option Plan to Lewis Gradon, Managing

Director and Chief Executive Officer of the

Company.

Click "Submit Vote" to lodge your vote.



## **Guestions?**



## This concludes the 2021 Annual Shareholders' Meeting.

## Thank you for attending.

